Mesenchymal Cell News Volume 5.49 | Dec 17 2013

Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients
This Phase I multicenter study aimed at assess the feasibility and safety of intravenous administration of third party-bone marrow derived mesenchymal stromal cells expanded in platelet lysate in 40 patients, experiencing steroid-resistant grade II-IV graft versus host disease. [Biol Blood Marrow Transplant] Abstract

Mechano Growth Factor E Peptide Regulates Migration and Differentiation of BMSCs
Scientists investigated on the effects of mechano growth factor (MGF) E peptide on bone marrow mesenchymal stem cells (BMSCs). Their results revealed that cells treated with MGF E peptide didn’t affect proliferation. [J Mol Endocrinol] Abstract

Novel Therapy for Insulin-Dependent Diabetes Mellitus: Infusion of In Vitro-Generated Insulin-Secreting Cells
Researchers present their experience of treating insulin-dependent diabetes mellitus with co-infusion of in vitro autologous adipose tissue-derived mesenchymal stem cells-differentiated insulin-secreting cells with hematopoietic stem cells. [Clin Exp Med] Abstract

Cytocompatibility Evaluation of Different Biodegradable Magnesium Alloys with Human Mesenchymal Stem Cells
Eight different magnesium alloys containing varying amounts of Al, Zn, Nd and Y were either incubated directly or indirectly with the osteosarcoma cell line Saos-2 or with uninduced and osteogenically-induced human mesenchymal stem cells isolated from bone marrow specimens obtained from the femoral shaft of patients undergoing total hip replacement. [J Mater Sci Mater Med] Abstract

Pre- and Postnatal Transplantation of Fetal Mesenchymal Stem Cells in Osteogenesis Imperfecta: A Two-Center Experience
Investigators report the clinical course of two patients with osteogenesis imperfecta who received prenatal human fetal mesenchymal stem cells (MSC) transplantation and postnatal boosting with same-donor MSCs. [Stem Cells Transl Med] Abstract | Press Release

Sox2 Suppression by miR-21 Governs Human Mesenchymal Stem Cell Properties
Scientists analyzed the microRNA (miRNA) profile of mesenchymal stem cells (MSCs) derived from amniotic fluid, bone marrow, and umbilical cord blood. They initially identified 67 different miRNAs that were expressed in all three types of MSCs but at different levels, depending on the source. [Stem Cells Transl Med] Abstract

Activity of Mesenchymal Stem Cells in Therapies for Chronic Skin Wound Healing
The authors outline several mechanisms by which mesenchymal stem cells can improve healing outcomes in these cases, including reducing tissue inflammation, inducing angiogenesis in the wound bed, and reducing scarring following the repair process. [Organogenesis] Abstract

Visit our reviews page to see a complete list of reviews in the mesenchymal cell research field.

Stem Cell Agency Board Funds More than $61 Million in Cancer, Sickle Cell Disease and Vision Loss and Sets New Focus
Reflecting the progress being made in moving the most promising therapies out of the lab and into clinical trials, the state stem cell agency, the California Institute for Regenerative Medicine voted to approve $61 million in funding for its third round of Disease Team awards. [California Institute for Regenerative Medicine]
Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mesenchymal cell community.

PhD Position – Recombinant Collagen Scaffold Design for Tuned Drug Release in Bone Repair (Fraunhofer)

PhD Position – Human Cell Isolation and Controlled Expansion for Tuned Drug Release in Bone Repair (Medicyte)

Postdoctoral Position – Tissue Engineering and Regenerative Medicine (RUNMC)

Postdoctoral Positions – Stem Cell and Regenerative Medicine (Universidad de Los Andes)

PhD Studentship – Mesenchymal Stem Cells as Endogenous Regulators of Inflammation (University of Birmingham)

Postdoctoral Research Fellows – Stem Cells (Wake Forest Institute for Regenerative Medicine)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.